
Tacrolimus
Tacrolimus is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after transplantation. Tacrolimus therapy can be associated with mild serum enzyme elevations, and it has been linked to rare instances of clinically apparent cholestatic liver injury. — LiverTox
- IUPAC 명칭
- (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
- 분자식
- C44H69NO12
- 분자량
- 804.0 g/mol
- 정확한 질량
- 803.48197664 Da
- XLogP3
- 2.7
- 위상 극성 표면적
- 178.0 Ų
- 수소 결합 공여체
- 3
- 수소 결합 수용체
- 12
- 공유결합 단위
- 1
- 정의된 입체중심
- 14
다른 이름
보고된 명칭 16개 더 보기
외부 데이터베이스 식별자
- ChEBI:CHEBI:61049
- ChEBI:CHEBI:93221
- ChEMBL:CHEMBL269732
- EPA DTXSID:DTXSID5046354
- PubMed:30545944
- PubMed:17965516
- PubMed:16702731
- PubMed:16021174
- PubMed:15896681
- PubMed:14661025
- PubMed:11145792
- PubMed:9857082
- PubMed:2445721
- PubMed:1715244
추가 과학 데이터베이스의 근거
EMBL-EBI ChEBI
tacrolimus (anhydrous)
A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.
- 처방
- C44H69NO12
- 평균 질량
- 804.031 g/mol
- 단일 동위원소 질량
- 803.48198 Da
- 형식 전하
- 0
- macrolide lactam — is a (CHEBI:145565)
- bacterial metabolite — has role (CHEBI:76969)
- immunosuppressive agent — has role (CHEBI:35705)
- bacterial metabolite — has role (CHEBI:76969)
- immunosuppressive agent — has role (CHEBI:35705)
- macrolide lactam — is a (CHEBI:145565)
추가 선별 명칭
이 출처의 상호 참조
- CAS: 104987-11-3 — KEGG COMPOUND
- CAS: 104987-11-3 — ChemIDplus
- CAS: 104987-11-3 — KEGG DRUG
- REGISTRY_NUMBER: 3647477 — Reaxys
- REGISTRY_NUMBER: 8821611 — Reaxys
- MANUAL_X_REF: C01375 — KEGG COMPOUND
- MANUAL_X_REF: D08556 — KEGG DRUG
- MANUAL_X_REF: DB00864 — DrugBank
- MANUAL_X_REF: EP184162 — Patent
- MANUAL_X_REF: FK5 — PDBeChem
- MANUAL_X_REF: LMPK04000003 — LIPID MAPS
- MANUAL_X_REF: US5665727 — Patent
매핑 기준: Exact CAS cross-reference in the ChEBI compound record. 출처 업데이트: 2019-12-03. 가져온 시각: 2026-08-31. 출처 기록 열기
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- LogP: 3.3 출처: DrugBank
- Melting Point: 126 °C 출처: DrugBank
- Solubility: Insoluble 출처: DrugBank
- IARC Carcinogenic Agent: Tacrolimus 출처: International Agency for Research on Cancer (IARC)
- IARC Carcinogenic Classes: Group 1: Carcinogenic to humans 출처: International Agency for Research on Cancer (IARC)
- IARC Monographs: Volume 137: (2026) Hydrochlorothiazide, Voriconazole, and Tacrolimus 출처: International Agency for Research on Cancer (IARC)
- Publication Year: 2026 online 출처: International Agency for Research on Cancer (IARC)
- Evaluation Year: 2024 출처: International Agency for Research on Cancer (IARC)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). 출처: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Њ±10%; in adults liver transplant patients is 22Њ±6%; in healthy subjects is 18Њ±5%. The absolute bioavailability in pediatric liver transplant patients was 31Њ±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition. 출처: Toxin and Toxin Target Database (T3DB)
- Signal: Danger 출처: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (92.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (91.5%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 출처: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement) 출처: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 82 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. 출처: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] 출처: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. 출처: European Chemicals Agency (ECHA)
- Signal: Danger 출처: Hazardous Substances Data Bank (HSDB)
- GHS Hazard Statements: H301: Toxic if swallowed [Danger Acute toxicity, oral] 출처: Hazardous Substances Data Bank (HSDB)
- Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) 출처: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: IDENTIFICATION AND USE: Tacrolimus is white to off-white crystalline powder. It is a calcineurin-inhibitor immunosuppressant available in several preparations. Tacrolimus in both oral capsules and a solution for IV injection is used for prophylaxis of organ rejection in patients receiving liver, kidney or heart transplants. Tacrolimus topical ointment is used as a second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children. HUMAN EXPOSURE AND TOXICITY: While most acute overdosages of tacrolimus at up to 30 times the intended dose have been asymptomatic and all patients recovered with no sequelae, some acute overdosages were followed by adverse reactions including tremors, abnormal renal function, hypertension, and peripheral edema. At therapeutic doses, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin, as well as an increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. While there a 출처: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: Signs and Symptoms of Overdose; Tacrolimus toxicity commonly presents as acute kidney injury. Close monitoring of serum creatinine, glomerular filtration rate, and urine output is necessary for patients on tacrolimus. Toxicity may also present as adverse effects, including tremors, electrolyte disturbances, and headaches. Monitor for neurotoxicity, nephrotoxicity, and hypertension. Investigations may indicate increased serum creatinine. An electrocardiogram should be obtained to rule out QT prolongation.; Management of Overdose; No specific antidote is currently available for tacrolimus toxicity, and the drug is not removed by hemodialysis. Management focuses on supportive care, including symptom monitoring and management. Consultation with the poison control center is recommended for current guidance and treatment recommendations. 출처: StatPearls
- Toxicity Summary: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. 출처: Toxin and Toxin Target Database (T3DB)
- Uses: THERAPEUTIC CATEGORY: Immunosupressant; dermatological treatment of atopic eczema 출처: Hazardous Substances Data Bank (HSDB)
- Uses: Immunosuppressive Agents 출처: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION 출처: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >25; Use (kg) in USA (2002): 45; Consumption (g per capita; approx.) in Germany (2009): 0.000305; Consumption (g per capita) in the USA (2002): 0.00016; Calculated removal (%): 6 출처: NORMAN Suspect List Exchange
- Uses: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis. 출처: Toxin and Toxin Target Database (T3DB)
매핑 기준: Existing checksum-valid CAS to unique PubChem CID match. 가져온 시각: 2026-08-31. 출처 기록 열기
과학적 분류와 유해성 주석은 맥락을 제공할 뿐이며, 위에 표시된 시장별 규제 판단을 대체하지 않습니다.
추가 출처 적용 범위 및 일치 상태
| 출처 | 결과 | 확인됨 |
|---|---|---|
| EMBL-EBI ChEBI | 정확히 일치 | 2026-08-31 |
| NIH PubChem PUG-View | 정확히 일치 | 2026-08-31 |
기록된 불일치는 출처를 확인했다는 유용한 근거이며, 해당 물질이 다른 곳에 존재하지 않는다는 주장이 아닙니다.
체크섬이 유효한 CAS 일치를 통해 2026-08-31에 NIH PubChem에서 가져왔습니다. 화학적 특성은 이 페이지의 규제 판단을 대체하지 않습니다.